Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ignyte Bio
San Francisco, California, United Statesignytebio.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Ignyte Bio is a biotechnology company builder and investor that focuses on developing optimized biologics for established therapeutic pathways. Founded by the leadership of Fairmount Funds, the company identifies validated drug targets and builds dedicated biotechnology entities to advance improved therapies, often utilizing antibody engineering through its partner, Paragon Therapeutics. Its portfolio includes prominent clinical-stage companies such as Viridian Therapeutics, Apogee Therapeutics, and Dianthus Therapeutics.
- Therapeutic areas
- HematologyImmunologyEndocrinologyNeurologyDermatologyPulmonology
- Modalities
- Monoclonal antibody
- Industry
- Investors
02
Partnerships
Fairmount Funds ManagementParagon Therapeutics
Beyond the preview
Go deeper on Ignyte Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ignyte Bio.